A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer.
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel (Primary) ; Ipatasertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 13 Oct 2023 Status changed from completed to discontinued. ( Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab anddocetaxel was challenging due to multiple study treatment modifications required to manage toxicity, making further enrollment inappropriate. )
- 14 Nov 2022 Status changed from active, no longer recruiting to completed.
- 17 Jan 2022 Status changed from recruiting to active, no longer recruiting.